Metabolic dysfunction increases risk for steatosis and fibrosis development: Study
USA: In a new study published in Clinical Gastroenterology and Hepatology, it was shown that metabolic dysfunction, as defined by the metabolic-associated fatty liver disease (MAFLD) criteria, is a major risk factor for steatosis and fibrosis development.The MAFLD criteria are intended to capture the disease's heterogeneity in order to improve patient categorization and therapy. However, as...
USA: In a new study published in Clinical Gastroenterology and Hepatology, it was shown that metabolic dysfunction, as defined by the metabolic-associated fatty liver disease (MAFLD) criteria, is a major risk factor for steatosis and fibrosis development.
The MAFLD criteria are intended to capture the disease's heterogeneity in order to improve patient categorization and therapy. However, as is well known, the metabolic parameters utilized in nomenclature are complicated and linked, and their nuanced contribution to the definition must be evaluated in order to appropriately quantify clinical significance and stratify the at-risk group.
Kajal Claypool and colleagues used two models, one for each metabolic component, to investigate the relative predictive relevance of the seven core metabolic parameters described by the MAFLD criteria for steatosis and fibrosis outcomes in a nationally representative cohort, NHANES 2017-2018. They defined hepatic steatosis as the median liver stiffness evaluated by vibration-controlled transient elastography, and fibrosis as the controlled attenuation parameter (CAP) at the higher sensitivity cut-off point. All of the models were adjusted for diabetes, obesity, ethnicity, age, and gender.
The key findings of this study were as follows:
1. Independent of excessive BMI and diabetes, the presence of two or more metabolic variables enhanced the likelihood of steatosis and fibrosis.
2. Individuals with two or more metabolic variables were considerably more likely to have steatosis and fibrosis.
3. Insulin resistance and enhanced central obesity, as defined by increased waist circumference, were the top two metabolic variables for steatosis by odds ratio and Nagelkerke R2.
4. Elevated waist circumference was linked with aOR: 5.98 for CAP 290 dB/m, whereas insulin resistance, as determined by the homeostatic model evaluation of insulin resistance, was associated with aOR: 3.96.
5. Elevated waist circumference was related to an aOR of 4.43 for LSM 8.2 kPa, whereas insulin resistance was associated with an aOR of 2.8.
"This study sheds insight on the characteristics that dominate the link between steatosis and fibrosis (e.g., visceral adiposity and insulin resistance), revealing that traits that are common in the United States, and is also associated with a higher risk of liver disease," concluded the authors.
Claypool, K., Long, M. T., & Patel, C. J. (2022). Waist circumference and insulin resistance are the most predictive metabolic factors for steatosis and fibrosis. In Clinical Gastroenterology and Hepatology. Elsevier BV. https://doi.org/10.1016/j.cgh.2022.05.021
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at email@example.com